BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction

Summary

This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are randomized to the treatment group will have the study drug injected into the solution that their donor lungs are kept in prior to transplant.

Timeline

Start

2026-07-01

Primary completion

2027-08

Completion

2027-12

Drugs

Indications

No indication recorded.